AQR Capital Management
KYTX icon

AQR Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

AQR Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,542
Closed -$81.3K – 3658
2025
Q3 		$81.3K Sell
13,542
-86,616
-86% -$346K ﹤0.01% 3387
2025
Q2 		$307K Buy
100,158
+29,101
+41% +$72K ﹤0.01% 2864
2025
Q1 		$137K Buy
+71,057
New +$210K ﹤0.01% 2957

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

AQR Capital Management's KYTX Position: Q4 2025 in Review

AQR Capital Management sold out of Kyverna Therapeutics (KYTX) in Q4 2025, closing a stake of 13,542 shares — an estimated $81.3K sold.

AQR Capital Management first reported a position in KYTX in Q1 2025 and held it in 3 quarters. The position peaked at $307K in Q2 2025. 99 funds tracked by Wall St. Rank hold KYTX as of Q4 2025.

  • AQR Capital Management reported no remaining Kyverna Therapeutics position as of Q4 2025 after selling out during the quarter.
  • AQR Capital Management sold 13,542 Kyverna Therapeutics shares in Q4 2025, an estimated $81.3K.
  • AQR Capital Management first reported a position in Kyverna Therapeutics in Q1 2025 and held it in 3 quarters.
  • AQR Capital Management's Kyverna Therapeutics position peaked at $307K in Q2 2025.
  • 99 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q4 2025.

Based on AQR Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.